[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-digestive-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-digestive-system-neoplasm":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,79,102,134,153,175,195,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100614772","studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays-100614772",false,"NCT07283939","Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays","Inclusion Criteria:\n\n* \\* REGISTRATION ELIGIBILITY CRITERIA (STEP 1)\n\n  * Histologic confirmation of invasive cancer that is confirmed or suspected to arise from the gastrointestinal (GI) tract\n  * Any stage for which FOLFOX-based chemotherapy is a clinically-indicated, standard-of-care treatment (adjuvant, neoadjuvant, or first-line chemotherapy)\n  * Eligible primary tumor sites include the esophagus, gastroesophageal junction, stomach, small intestine, ampulla of Vater, appendix, colon, rectum, and cancers of unknown primary with suspected GI origin\n  * Prior systemic therapy for GI cancer (other than cycle 1 of FOLFOX-based chemotherapy) is not allowed. Prior radiation-sensitizing chemotherapy is permitted\n  * The planned duration of FOLFOX-based chemotherapy must be at least four cycles (1 cycle = 14 days)\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must be completed 1 to 8 days prior to registration\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must include minimum ordered doses of oxaliplatin (≥ 65 mg\u002Fm\\^2) and infusional 5-FU (2400 mg\u002Fm\\^2\u002F46 hours). Use of the 5-FU bolus is at the discretion of the treating physician\n  * Patients who require primary prophylactic white blood cell growth factor with cycle 1 of FOLFOX chemotherapy due to high risk for fever and neutropenia are not eligible\n  * History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs, to fluorouracil, or to leucovorin, and the excipients in their formulations are not eligible\n  * Age ≥ 18 years\n  * ECOG performance status ≤ 2\n  * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3\n  * Platelet count ≥ 100,000\u002Fmm\\^3\n  * Total bilirubin ≤ 3 x upper limit of normal (ULN)\n  * AST (SGOT)\u002FALT (SGPT) ≤ 5 x upper limit of normal (ULN)\n  * Calc. creatinine clearance ≥ 30 mL\u002Fmin\n  * Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 30 days prior to registration is required\n  * Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression\n  * Patients with known HIV infection are eligible if receiving effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration\n  * Patients with known chronic hepatitis B virus (HBV) infection are eligible if HBV DNA is undetectable when measured within 6 months prior to registration\n  * Patients with a known history of hepatitis C virus (HCV) infection are eligible if HCV RNA is undetectable when measured at least 12 weeks after completion of antiviral therapy\n  * Patients with known history or current symptoms of cardiac disease are eligible if the New York Heart Association Functional Classification is class I or II\n  * Patients with a known history of congenital long QT syndrome are ineligible\n  * Patients with known DPD deficiency are ineligible\n* \\* NON-PATIENT (ONCOLOGY PHYSICIAN OR ONCOLOGY ADVANCED PRACTICE PROVIDER ELIGIBILITY:\n\n  * The non-patient provider participant is a medical oncologist or oncology advanced practice provider with responsibility for signing and making necessary modifications to chemotherapy orders for a subject assigned to the intervention arm (Arm B). Non-patient participants may not be enrolled more than once over the course of the study\n  * The non-patient participant must be proficient in the English language\n  * The non-patient participant must be age 21 years or older",true,"ALL","18 Years",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.",[27,28,29,30,31,32,33,34,35,36],"Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2026-02-13",{"date":45,"type":21},"2030-05-02",{"name":47,"class":48},"Alliance for Clinical Trials in Oncology","OTHER",344,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100132279","data-collection-for-the-assessment-of-acute-and-late-normal-tissue-in-patients-treated-with-proton-therapy-100132279","NCT00991094","Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy","Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults","Inclusion Criteria:\n\n* All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol\n* Patients must sign a study-specific consent form prior to study entry\n\nExclusion Criteria:\n\n* Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site",{"count":58,"type":21},5000,"OBSERVATIONAL","This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.",[62,31,63,64,65,66,67,34,68],"Breast Carcinoma","Genitourinary System Carcinoma","Head and Neck Carcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Lung Carcinoma","Malignant Central Nervous System Neoplasm","Malignant Solid Neoplasm","2026-06-10",{"date":71,"type":41},"2026-06-12",{"date":73,"type":41},"2005-05-27",{"date":75,"type":21},"2027-12-31",{"name":77,"class":48},"M.D. Anderson Cancer Center",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":78},"100628070","phase-1-vasodilator-therapy-with-isosorbide-mononitrate-or-diltiazem-to-reduce-vasotoxicity-in-patients-with-gastrointestinal-cancer-receiving-fluoropyrimidine-therapy-100628070","NCT07456852","Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","Vasotoxicity Surveillance Using EndoPAT: The VASA Pilot Study","Inclusion Criteria:\n\n* REGISTRATION: Age ≥ 18 years\n* REGISTRATION: Histologically or cytologically confirmed gastrointestinal malignancy (colon, rectal, gastric, esophageal, or other GI cancer) for which fluoropyrimidine therapy (5-FU or capecitabine) is indicated, either as single agent or in combination with other systemic therapy\n* REGISTRATION: Planned initiation of 5-FU (infusional) or oral capecitabine therapy, either as standard chemotherapy or as a radiosensitizer\n* REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* REGISTRATION: Ability to return to Mayo Clinic for baseline and follow-up EndoPAT testing, electrocardiogram (ECG), Holter monitoring, and blood draws\n* REGISTRATION: Provide written informed consent\n* REGISTRATION: Adequate baseline hemodynamic status: systolic blood pressure ≥ 120 mmHg and resting heart rate ≥ 70 beats\u002Fminute (to ensure safety for potential vasodilator therapy in Phase II)\n* RANDOMIZATION: Completed all phase I baseline and follow-up assessments, including EndoPAT, ECG, high-sensitivity cardiac troponin T (hs-TnT), and Holter monitoring\n* RANDOMIZATION: Demonstrated a ≥ 20% decline in reactive hyperemia index (RHI) from baseline at either phase I follow-up assessment as measured by EndoPAT\n* RANDOMIZATION: Adequate hemodynamic status prior to randomization: systolic blood pressure ≥ 120 mmHg and resting heart rate ≥ 70 beats\u002Fminute\n* RANDOMIZATION: Ability to tolerate and comply with study medication (isosorbide mononitrate, diltiazem, or placebo) per investigator assessment\n* RANDOMIZATION: Willingness to initiate study medication 5 days before and continue through the assigned fluoropyrimidine treatment cycle\n* RANDOMIZATION: Provide written informed consent for randomization phase\n\nExclusion Criteria:\n\n* REGISTRATION: Current or planned treatment with long-acting nitrates or calcium channel blockers at the time of fluoropyrimidine initiation\n* REGISTRATION: Known hypersensitivity or contraindication to nitrates or calcium channel blockers\n* REGISTRATION: Baseline systolic blood pressure \\\u003C 120 mmHg or resting heart rate \\\u003C 70 beats\u002Fminute\n* REGISTRATION: History of myocardial infarction ≤ 6 months prior to registration, or symptomatic heart failure \\[decompensated or New York Heart Association (NYHA) III-IV\\] requiring ongoing therapy\n* REGISTRATION: Recent acute coronary syndrome or coronary revascularization within 3 months of enrollment\n* REGISTRATION: High-grade atrioventricular (AV) block without pacemaker\n* REGISTRATION: Use of PDE-5 inhibitors \\[e.g. sildenafil (Viagra)\\] within 48 hours of enrollment\n* REGISTRATION: Uncontrolled intercurrent illness including but not limited to: unstable angina, symptomatic arrhythmias, uncontrolled infection, or psychiatric\u002Fsocial conditions limiting compliance with study requirements\n* REGISTRATION: Physical inability to undergo EndoPAT testing (e.g., digital amputation, severe hand deformity, or other limiting condition)\n* REGISTRATION: Pregnant or nursing persons\n* REGISTRATION: Concurrent enrollment in another interventional clinical trial that, in the opinion of the investigator, would interfere with study endpoints",{"count":87,"type":21},60,[89,90],"PHASE1","PHASE2","This phase I\u002FII trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluoropyrimidine therapy. Some patients develop chest pain (possibly even a heart attack, a drop in heart function, or a rhythm abnormality) during treatment with a class of cancer drugs known as fluoropyrimidines, which include 5-Fluorouracil (5-FU) and capecitabine. These side effects are believed to be due to the development of an abnormal reactivity of the blood vessels referred to as vasospasm. Vasotoxicity is damage or toxicity inflicted upon blood vessels (vascular system), often causing dysfunction, remodeling, or narrowing (vasoconstriction). It is a broad term used to describe the detrimental effects of certain agents, such as chemotherapy drugs. Researchers want to evaluate how often the reactivity of blood vessels becomes abnormal, during the treatment with 5-FU or capecitabine and how clinically relevant and controllable\u002Fpreventable this phenomenon is in patients with gastrointestinal cancer.",[34],"2026-05-29",{"date":95,"type":41},"2026-06-02",{"date":97,"type":41},"2026-04-30",{"date":99,"type":21},"2030-04-30",{"name":101,"class":48},"Mayo Clinic",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":123,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":132,"locationsCount":78},"100640818","studying-the-workflow-of-the-american-college-of-surgeons-geriatric-surgery-program-to-improve-clinical-outcomes-in-older-adults-undergoing-surgery-at-the-james-cancer-hospital-100640818","NCT07606287","Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital","Implementation of the American College of Surgeons Geriatric Surgery Verification Program at the James Cancer Hospital","Inclusion Criteria:\n\n1. Patient records for adults aged 65 years or older\n2. Patient records with a surgical encounter or preoperative evaluation within participating James Cancer Hospital surgical oncology services during the rollout period\n3. Patient records with data available in institutional electronic health record or institutional data systems\n4. Clinical staff age 18 years or older who are employed or credentialed at The Ohio State University Wexner Medical Center and work within clinical areas affected by ACS Geriatric Surgery Verification implementation\n\nExclusion Criteria:\n\n1. Patient records for encounters occurring only at outside institutions or non-James hospitals within the enterprise\n2. Patient records missing all primary outcome fields after data quality checks\n3. Clinical staff who are trainees, including medical students, physician assistant students, nursing students, resident physicians, or fellows\n4. Clinical staff whose employment, visa, or institutional status would make participation sensitive under institutional policy, if applicable",{"count":110,"type":21},4000,[24],"This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital. The program is designed to improve surgical care for adults age 65 and older by helping care teams identify and address age-related needs before, during, and after surgery.\n\nOlder adults with cancer may have concerns related to physical function, memory or thinking, medications, social support, and goals of care. If these needs are not recognized, patients may be at higher risk for complications, longer hospital stays, readmission, or discharge to a facility instead of home.\n\nThe ACS GSV Program includes standards for geriatric surgery leadership, goals-of-care discussions, screening for age-related vulnerabilities, care plans for identified needs, age-friendly perioperative care, and regular review of surgical outcomes. This study will evaluate how well these standards are adopted across surgical oncology services and whether implementation is associated with better outcomes, such as shorter hospital stays, fewer complications, fewer readmissions, and improved discharge outcomes.\n\nThe results may help improve surgical care workflows for older adults undergoing cancer surgery.",[62,34,114,115,116,117,68,118,119,120,121,122],"Malignant Female Reproductive System Neoplasm","Malignant Genitourinary System Neoplasm","Malignant Head and Neck Neoplasm","Malignant Nervous System Neoplasm","Malignant Thoracic Neoplasm","Skin Neoplasm","Soft Tissue Neoplasm","Central Nervous System Neoplasm","Endocrine Gland Neoplasms",[124,125],"geriatric surgery verification","oncogeriatrics","NOT_YET_RECRUITING","2026-05-27",{"date":93,"type":41},{"date":130,"type":21},"2026-06-15",{"date":75,"type":21},{"name":133,"class":48},"Ohio State University Comprehensive Cancer Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":78},"100453051","molecular-epidemiology-of-biliary-tree-cancers-100453051","NCT05179486","Molecular Epidemiology of Biliary Tree Cancers","Inclusion Criteria:\n\n* Pathologically or radiologically confirmed diagnosis of CGC or GBC\n* With or without prior radiation or chemotherapy\n* All United States of America (USA) and non USA residents\n* No age, gender, or racial restriction\n* Healthy control with no current or history of cancer\n* Healthy controls are USA and non USA residents\n* Healthy controls are matched to the cases in age (5 years), gender, and race\n* Healthy controls are friends and spouses of patients with other than gastro-intestinal (GI) cancers\n* Chronic Liver Disease (CLD) controls with no current or history of cancer\n* CLD controls are USA and non USA residents\n* CLD controls are frequency matched to CGC cases by age (5 years), gender, and race\n* CLD controls are patients are diagnosed with or without liver biopsy (core or fine needle aspiration)\n* CLD controls must not have evidence liver cancer diagnosis by computed tomography (CT) or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* None",{"count":141,"type":21},1500,"This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliary tree cancer is affected by different treatments, and why some people's cancer responds differently than others.",[144,34],"Cholangiocarcinoma","2026-04-14",{"date":147,"type":41},"2026-04-17",{"date":149,"type":41},"2017-09-25",{"date":151,"type":21},"2027-02-02",{"name":77,"class":48},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100609518","surgical-thromboprophylaxis-practices-in-oncology-patients-within-the-ncorp-network-stop-vte-study-100609518","NCT07215624","Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study","Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network (STOP-VTE)","STOP-VTE","Inclusion Criteria:\n\nSURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:\n\n\\* Any surgeon performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgeons do not need to be involved in research or have a Cancer Therapy Evaluation Program Identification (CTEP ID) to participate in this study\n\nSURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 0 ENROLLMENT:\n\n\\* APPs providing postoperative care to patients operated by surgeons performing gastrointestinal, genitourinary, or gynecologic cancer surgery within an NCORP site, including general surgeons, surgical specialists, urologists, and gynecologists. Surgical APPs do not need to be involved in research or have a CTEP ID to participate in this study\n\nSURGEON ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:\n\n\\* Must have completed the STOP-VTE Survey - Surgeon electronically (preferred) or on paper and have it transferred to Research Electronic Data Capture (REDCap) by the contact person(s)\n\nSURGICAL APP ELIGIBILITY CRITERIA FOR OPEN STEP 1 ENROLLMENT:\n\n\\* Must have completed the STOP-VTE Survey - APP electronically (preferred) or on paper and have it transferred to REDCap by the contact person(s)\n\nSITE ELIGIBILITY PART 1-SITE ENROLLMENT IN OPEN:\n\n\\* Have at least one eligible surgeon or surgical APP who completed the STOP-VTE Survey - Surgeon\u002FAPP\n\nExclusion Criteria:\n\n* N\u002FA",{"count":162,"type":21},500,"This study evaluates the use of extended venous thromboembolism prophylaxis (ePPx) following abdominopelvic cancer surgery within the NCI Community Oncology Research Program (NCORP) network, targeting surgeons and surgical advanced practice providers (APPs).",[34,114,115],"2026-04-06",{"date":167,"type":41},"2026-04-08",{"date":169,"type":41},"2026-01-15",{"date":171,"type":21},"2027-06-01",{"name":173,"class":48},"Wake Forest University Health Sciences",59,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":78},"100581839","phase-2-fucoidan-for-preventing-chemotherapy-related-fatigue-in-patients-with-gastrointestinal-or-gynecological-cancer-100581839","NCT06855524","Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer","Fucoidan for Patients With Chemotherapy-Related Fatigue: A Double-Blind, Randomized, Placebo-Controlled Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1\n* Starting platinum-based doublet\u002Ftriplet therapy for gynecologic or gastrointestinal cancer in the non-curative setting, with at least 16 weeks of chemotherapy and\u002For immunotherapy planned prior to registration; able to start study treatment ≤ 7 days prior to starting chemotherapy\n* Life expectancy at least 6 months\n* Hemoglobin ≥ 10 g\u002FdL (obtained ≤ 30 days prior to registration)\n* Creatinine ≤ 1.5 x upper normal limit (UNL) OR calculated creatinine clearance ≥ 50 ml\u002Fmin using the Cockcroft-Gault (obtained ≤ 30 days prior to registration)\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 1.5 x UNL; \\[≤ 5 x upper limit of normal (ULN) for patients with liver involvement\\] (obtained ≤ 30 days prior to registration)\n* Ability to complete patient questionnaires alone or with assistance and to be willing to be contacted by study staff\n* Provide written informed consent\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Willing to use a highly effective method of contraception from the first dose of study medication through 30 days after the last dose of study medication, for persons of childbearing potential or persons able to father a child only\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Known hypersensitivity to fucoidan or seaweed products\n* Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for ≥ 1 month prior to registration and plans to continue such for 8 weeks. Exercise is allowed\n* Psychiatric disorder such as untreated\u002Funcontrolled depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia (defined per medical history)\n* Surgery that required general anesthetic ≤ 4 weeks prior to registration\n* Malnutrition, active infection, severe depression, significant pulmonary disease, and\u002For cardiovascular disease that the attending physician feels could be causing the patient's fatigue\n* Use of any over-the-counter herbal\u002Fdietary supplement marketed for fatigue or energy (for example, products containing ginseng, rhodiola rosea, guarana, or anything called an \"adaptogen\"), including current use of fucoidan\n* Current use of warfarin, heparin, enoxaparin, or a novel anticoagulant or known bleeding disorder\u002Fabnormal prothrombin time (PT)\u002Fpartial thromboplastin time (PTT) at baseline\n* Current use of bevacizumab\n* Untreated thyroid conditions\n* Use of chemotherapy and\u002For immunotherapy ≤ 90 days prior to registration\n* Unwillingness to follow study related procedures\n* Inability to provide informed consent",{"count":183,"type":21},34,[90],"This clinical trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI) or gynecological (GYN) cancer. Fatigue poses a burden in patients with malignancies undergoing systemic chemotherapy. Fucoidan is a dietary supplement made of complex sugar that contain sulfate groups attached to their sugar units (sulfated polysaccharide) which found in brown seaweed. It is thought to have anti-inflammatory, anti-viral, anti-thrombotic, anti-diabetic, and anti-tumor effects in pre-clinical models. Giving fucoidan may be effective in preventing chemotherapy-related fatigue in patients with GI or GYN.",[34,114],"2026-02-20",{"date":189,"type":41},"2026-02-24",{"date":191,"type":41},"2025-03-06",{"date":193,"type":21},"2027-02-28",{"name":101,"class":48},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":212,"locationsCount":78},"100410835","evaluation-of-portal-vein-stenting-in-patients-with-portal-vein-stenosis-and-gastrointestinal-cancers-100410835","NCT04629677","Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers","Prospective Evaluation of Portal Vein (PV) Stenting in Patients With PV Stenosis and Gastrointestinal Malignancies","Inclusion Criteria:\n\n* COHORT A: All patients will undergo initial staging and treatment as per the institution standard of care. Patients will be considered eligible for porto-mesenteric venous stenting (PVS) if:\n\n  * There is \\> 75% porto-mesenteric venous stenosis in either main portal vein (PV), left PV, right PV, or the superior mesenteric vein (SMV), even in absence of symptoms of portal hypertension\n  * Patients presented with any degree of vascular narrowing of said vessels and symptomatic portal hypertension including variceal bleeding, refractory ascites, abdominal pain, intestinal edema, or diarrhea after exclusion of tumor-related causes as direct tumor invasion or peritoneal dissemination\n* COHORT B: Patients who have thrombosis\u002Fstenosis of the main portal vein but who did not undergo stenting",{"count":203,"type":21},150,"This study collects information about the safety and effect of portal vein stenting in gastrointestinal cancer patients with portal vein stenosis. This study may help researchers learn how long the portal vein stays open and free from blockage and the effects of portal vein stenting on patients' overall well-being.",[34],"2026-01-08",{"date":208,"type":41},"2026-01-12",{"date":210,"type":41},"2019-04-02",{"date":97,"type":21},{"name":77,"class":48},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100347203","phase-2-2-versus-6-hour-oxaliplatin-infusions-in-patients-with-gastrointestinal-cancers-100347203","NCT03800693","2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers","Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy and Pharmacokinetics in Patients With Gastrointestinal Cancers","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Confirmed diagnosis of a gastrointestinal cancer\n* Plan for 4 or more cycles of FOLFOX6 (fluorouracil \\[with leucovorin\\] and oxaliplatin) containing chemotherapy\n* Histologically confirmed, measurable or evaluable disease. Patients with advanced or metastatic disease should have at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Patients in the adjuvant treatment setting planned to have \\> 4 cycles of FOLFOX-containing chemotherapy are eligible and will be followed per standard of care\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FµL (no white blood cell growth factors allowed to meet requirement)\n* Platelets ≥ 75,000\u002FµL (may be transfused up to 72 hours prior to day 1 to meet requirement)\n* Hemoglobin ≥ 8 g\u002FdL (may be transfused up to 72 hours prior to day 1 to meet requirement)\n* Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault, to preserve similar dosing (85 mg\u002Fm²) for analysis\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN)\n* Signed informed consent\n* Adequate birth control when appropriate\n\nExclusion Criteria:\n\n* Any preexisting grade 2 or higher peripheral neuropathy\n* Patients currently receiving anticancer therapies or who have received any focal or systemic anticancer therapy within 14days of the start of FOLFOX6\n* Known intolerance or hypersensitivity to any agent in FOLFOX6 or concurrent agents\n* Patients who have any known severe and\u002For uncontrolled medical conditions such as:\n\n  * Unstable angina pectoris, symptomatic heart failure; (New York Heart Association class III or IV), myocardial infarction ≤ 6 months prior, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease\n  * Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, or decompensated liver disease\n* Patients with any history of severe hemorrhage requiring ≥ 4 units of packed red blood cells (RBCs) in a 48-hour period\n* Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study\n* Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 14days prior to dosing\n* Pregnant or nursing (lactating) women\n* Women of childbearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during the study and 8 weeks after. Highly effective contraception methods include combination of any two of the following:\n\n  * Use of oral, injected or implanted hormonal methods of contraception or;\n  * Placement of an intrauterine device (IUD) or intrauterine system (IUS);\n  * Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002F vaginal suppository;\n  * Total abstinence or;\n  * Male\u002Ffemale sterilization Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential",{"count":87,"type":21},[90],"This phase II trial studies how well giving oxaliplatin over 6 hours works in treating nerve damage in patients with gastrointestinal cancers. Oxaliplatin can cause side effects such as nerve damage that may delay or reduce the dose of oxaliplatin. Giving oxaliplatin over a longer period of time (6 hours) may prevent or delay the development of nerve damage, which may keep patients on standard doses of chemotherapy longer, without having to delay treatment.",[34],"2025-11-05",{"date":226,"type":41},"2025-11-06",{"date":228,"type":41},"2019-03-14",{"date":230,"type":21},"2026-09-17",{"name":232,"class":48},"Emory University",3]